Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

10/2/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MDGL alert in real time by email

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8^th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.

The fireside chat will be webcast live and may be accessed here or by visiting Madrigal's website's Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact

Tina Ventura, [email protected]

Media Contact

Christopher Frates, [email protected]

Get the next $MDGL alert in real time by email

Date	Price Target	Rating	Analyst
6/28/2024		Neutral	Cantor Fitzgerald
6/11/2024	$382.00	Outperform	Wolfe Research
4/22/2024	$150.00	Underperform	BofA Securities
3/15/2024	$155.00 → $270.00	Sell → Neutral	B. Riley Securities
3/6/2024	$382.00	Buy	Citigroup
2/26/2024	$155.00	Neutral → Sell	B. Riley Securities
12/20/2022	$170.00 → $250.00	Outperform	Oppenheimer
12/19/2022		Underperform → Mkt Perform	Raymond James

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Chat with this insight

Recent Analyst Ratings for $MDGL

$MDGL Press Releases

Fastest customizable press release news feed in the world

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

$MDGL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

$MDGL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Madrigal Pharmaceuticals

Wolfe Research initiated coverage on Madrigal Pharmaceuticals with a new price target

BofA Securities initiated coverage on Madrigal Pharmaceuticals with a new price target

$MDGL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$MDGL FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

$MDGL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Huntsman Carole sold $218,041 worth of shares (688 units at $316.92), decreasing direct ownership by 6% to 10,785 units (SEC Form 4)

Director Levy Richard S exercised 5,000 shares at a strike of $7.36 and sold $1,750,000 worth of shares (5,000 units at $350.00) (SEC Form 4)

Director Levy Richard S exercised 5,000 shares at a strike of $7.36 and sold $1,504,703 worth of shares (5,000 units at $300.94) (SEC Form 4)

$MDGL Market Insights

Live Market Insights

Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals

JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $385

Cantor Fitzgerald Initiates Coverage On Madrigal Pharmaceuticals with Neutral Rating

$MDGL SEC Filings

SEC Form S-8 filed by Madrigal Pharmaceuticals Inc.

SEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.

SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

$MDGL Leadership Updates

Live Leadership Updates

$MDGL Financials

Live finance-specific insights

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Recent Analyst Ratings for
$MDGL

$MDGL
Press Releases

$MDGL
Large Ownership Changes

$MDGL
Analyst Ratings

$MDGL
Insider Purchases

$MDGL
FDA approvals

$MDGL
Insider Trading

$MDGL
Market Insights

$MDGL
SEC Filings

$MDGL
Leadership Updates

$MDGL
Financials